Endoplasmic reticulum-Golgi intermediate compartment protein 2 (ERGIC2)

Endoplasmic reticulum-Golgi intermediate compartment protein 2 (ERGIC2) is a transmembrane protein localized at the interface between the endoplasmic reticulum (ER) and Golgi apparatus, encoded by the ERGIC2 gene on chromosome 12p11[2][5]. ERGIC2 is a member of the emp24/p24 protein family and is primarily implicated in the trafficking of proteins from the ER to the Golgi, functioning as part of a complex with ERGIC3 and ERGIC32 to shuttle cargo proteins, including gap junction proteins[1][3][6]. It has two hydrophobic transmembrane domains anchoring it in the ER, with a major luminal domain[2]. Beyond its role in vesicle transport, ERGIC2 has been described as a candidate tumor suppressor in prostate cancer, mediating cell growth arrest, senescence, and reduced invasiveness of cancer cells[2][5]. Disruption of ERGIC2 affects intracellular transport, alters gap junction formation, and contributes to cardiac and bone pathologies in model systems[1][4]. The protein has also been explored as a diagnostic biomarker for osteoporosis and other diseases due to altered expression levels in pathologies[4]. ERGIC2 interacts with several other proteins (e.g., protein elongation factor 1alpha, beta-amyloid, and otoferlin), suggesting roles extending beyond cargo trafficking[2][4]. No approved drugs directly target ERGIC2, but bioinformatics analyses suggest potential modulation by environmental agents and therapeutics affecting ER stress or protein trafficking[4].

Other names

PTX1CDA14Erv41ERGIC and Golgi 2ERV41CD14 proteincd002

Not fully established; drugs likely affect ERGIC2 via modulation of ER stress response and protein trafficking[4]